DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV

Their core work

DZNE is Germany's dedicated research center for neurodegenerative diseases — Alzheimer's, Parkinson's, ALS, and frontotemporal dementia. They combine molecular and cellular neuroscience with advanced brain imaging, computational neuroscience, and clinical biomarker research to understand why specific neurons die and how to prevent it. DZNE also contributes significantly to European brain research infrastructure through the Human Brain Project, building simulation platforms, neuroinformatics tools, and federated computing resources. Their work spans from fundamental mechanisms (protein aggregation, microglia signaling, nuclear architecture) to translational efforts like vaccine development against neurodegeneration.

What they specialise in

How they've shifted over time

In the early period (2015–2018), DZNE focused heavily on large-scale brain modeling and infrastructure — participating in the Human Brain Project, building neuroinformatics tools, and working on brain-wide transcriptome reconstruction and simulation. Their disease work centered on synaptic dysfunction and Alzheimer's-related neuroinflammation. From 2019 onward, the focus shifted toward disease-specific molecular mechanisms: Parkinson's mitochondrial pathways, ALS/FTD vaccine strategies, nuclear architecture changes during ageing, and microglia-synapse communication. This reflects a move from broad computational neuroscience toward precision disease biology and translational interventions.

DZNE is moving from infrastructure-heavy brain modeling toward targeted molecular and cellular disease research with translational potential, particularly in Parkinson's, ALS, and microglia biology.

How they like to work

DZNE operates as both a project leader and a strong consortium partner, coordinating 11 of 28 projects — including several ERC grants and Marie Curie fellowships that reflect individual PI excellence. As a participant, they join large flagship consortia like the Human Brain Project (89+ partners) and IMI-funded pharma collaborations (PHAGO, IMPRiND). With 253 unique partners across 26 countries, they function as a well-connected hub rather than a closed network, comfortable in both small focused teams and massive pan-European platforms.

DZNE has collaborated with 253 unique partners across 26 countries, making it one of the most networked neuroscience centers in Europe. Their partnerships span academic institutions, clinical centers, computing infrastructure providers, and pharmaceutical companies through IMI joint undertakings.

What sets them apart

DZNE is one of the few European research centers exclusively dedicated to neurodegenerative diseases, giving it unmatched depth across Alzheimer's, Parkinson's, ALS, and FTD. Unlike university departments that cover neuroscience broadly, DZNE combines molecular disease biology, advanced imaging, computational modeling, and clinical biomarkers under one roof — all focused on neurodegeneration. Their dual strength in fundamental research (6 ERC/MSCA PI grants) and large consortium participation (HBP, IMI pharma partnerships) makes them an ideal partner for projects that need both scientific depth and infrastructure reach.

Highlights from their portfolio

• LLPS-NMR
  Largest single grant (EUR 2.46M ERC Consolidator), investigating liquid-liquid phase separation by NMR — a biophysics approach with direct relevance to protein aggregation in neurodegeneration.
• MicroSynCom
  EUR 1.69M ERC grant coordinated by DZNE, pioneering in vivo two-photon imaging of how microglia communicate with synapses during learning — a rapidly growing research frontier.
• DPR-VAX
  A vaccine approach to prevent ALS and FTD in C9orf72 mutation carriers — one of the most translational and clinically ambitious projects in DZNE's portfolio.